Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Noni warning letter

This article was originally published in The Tan Sheet

Executive Summary

Claims that Noni Juice Liquid Herbal Supplement and Noni Extra Strength Cleansing Formula AM/PM treat diabetes, asthma, cataracts, high blood pressure, breast cancer, depression and migraine render the products unapproved new drugs, FDA tells Carolina, Puerto Rico-based Mundo Natural in an April 29 warning letter. Similar claims about relief of arthritis, headaches and the immune system made for other noni juice products earned warning letters for three different companies in 2002 (1"The Tan Sheet" July 15, 2002, p. 9)...

You may also be interested in...

FDA Warning Letters Increasingly Targeting Internet Claims

More than 80% of the warning letters concerning OTC drug and dietary supplement products sent in the last few months have focused on Internet claims

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding

GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts